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ABSTRACT 
Microfluidic devices are a good example of the collaboration of chemical, biological, and engineering sciences. Microfluidic devices emerge as an in 
fluent technology which provides an alternative to conventional laboratory methods. These devices are employed for the precise handling and 
transport precise quantities of drugs without toxicity. This system is emerging as a promising platform for designing advanced drug delivery 
systems and analysis of biological phenomena on miniature devices for easy diagnosis. Microfluidics enables the fabrication of drug carriers with 
controlled geometry and specific target sites. Microfluidic devices are also used for the diagnosis of cancer circulating tumor cells. In the current 
review, different microfluidic drug delivery systems and diagnostic devices have described.  
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INTRODUCTION 
Microfluidic devices are an excellent tool for drug delivery and 
evaluation of drug effectiveness at the cellular level. Microfluidics 
devices consist of a micro-electro-mechanical system. In recent 
years the microfluidic devices are emerging as an important tool for 
cancer detection. These devices are used to analyze the fluids which 
are present in the micrometer-sized channels. There are many types 
of microfluidic devices that have been developed [1]. Cancer is also 
known as a malignant neoplasm, which includes a broad group of 
diseases having unregulated cell growth. In this disease, there is 
uncontrollable division and growth, which causes the formation of 
malignant tumors. This malignant tumor can invade multiple organs 
and spread to the whole body. The leading cause of death 
throughout the world is due to cancer [2]. At present many 
treatment options are available for cancer, which includes surgery, 
chemotherapy, radiation therapy, and palliative care. All the above 
treatments depend upon the type, location, and grade of cancer [3]. 
These treatments had disadvantages as these are very expensive and 
had various side effects. Circulating tumor cells (CTCs) are rare 
cancer circulating in the blood vessels in cancer metastasis. The 
detection of CTCs provides a rapid and less painful diagnosis method 
as compared to tissue biopsy. This method is a very good alternative 
to the previous invasive biopsy. It is also termed as liquid biopsy as 
only blood is withdrawn for cancer detection [4]. Rapid research is 
going on to develop microfluidic devices for drug delivery and 
detection of CTCs. The most widely accepted devices are 
chromatography, quantum dots, surface plasmon resonance, 
amperometric based sensing, and nuclear magnetic resonance [5]. In 
this review, types of microfluidic devices, drug delivery, and 
screening have been described. The review is based on data 
obtained from Pubmed (http://www.ncbi.nlm.gov//pubmed) and 
Google scholar with preference given to the data obtained during the 
last 10 y. The research items were varied. The main research terms 
were microfluidic devices, microfluidic drug delivery system, 
microscale channels, microneedles for drug delivery, circulating 
tumor cells, diagnosis of CTCs by the microfluidic system, lab-on-
chip and various combinations of these trems.  
Microfluidic drug delivery system 
Drug delivery using microfluidic devices on unhealthy tissues is 
done with high precision and a localized manner. Drug delivery is 
done by small particles in the form of bio capsules, microparticles, 
and nanoparticles. Another drug delivery system used is the 
microneedles. Microfluidic devices have many advantages over the 
conventional delivery system, such as precise target delivery, 
controlled release, precise dosage, and multiple dosages. These 
devices are used for the direct drug delivery and fabrication of drug 
carriers. The side effects of another system that are overcome in this 
system are toxicity, inflammation, and wastage. Microfluidics drug 
systems are used for peptides, proteins, and DNA based drugs to the 
target sites. This method also protects drugs from enzymatic 
degradation and the immune response of the host body [6]. 
Fabrication of drug carriers 
The drugs for proper action should reach the target organ without 
any damage. It should be protected from stomach acid, enzymes, and 
immune cells. The drug carriers of different polymer materials are 
used as drug carriers [7]. Now day's microfluidic devices are used 
for the fabrication of drug carriers by mixing different particles. The 
drug carrier should be biodegradable, biocompatible, and nontoxic. 
The polymers used as drug carriers are made more suitable by 
modifying using microfluidic devices [8]. This system helps to 
fabricate uniform particles and thus provides better bioavailability 
and controlled release of drugs. A microfluidic device fabricates to 
produce nanoparticles from PLGA-PEG and PLGA. The Microfluidic 
system also enhances the ratio of drug load into the particle and 
encapsulation of multiple drugs into one particle by mixing particles 
of different nature and phases [9].  
Microfluidic devices can fabricate drug carriers from nano to micro 
size and also maintain the uniform size. The self-assembled 
microfluidic fabrication is done by simple micromixer, 
hydrodynamic flow focusing and staggered herringbone micromixer 
(fig. 1-3). In hydrodynamic flow, a core of carrier solution, which 
consists of a surfactant mixer, is focused on the microchannel by 
surrounding streams of the miscible buffer. The microfluidic devices 
can also control the uniformity of the drugs carrier by geometry, 
flow rates, and diffusion coefficient of miscible streams. Micromixers 
are of two types active and passive depends upon the force applied. 
In an active mixer, the external source is used to mix two fluids of 
different phases. The forces like acoustic and ultrasonic waves, 
magnetic particles are used to exert force for mixing the particles. In 
the passive type, mixing depends upon the hydrodynamic flow of 
fluids no external force is applied as shown in fig. 1 [10]. Staggered 
herringbone mixer depends upon the chaotic advection. It consists 
of repeated patterns of grooves on the bottom surface of the 
microchannel. The grooves internally contain two channels of 
different lengths (one longer and another shorter) which are 
connected at an angle of 45 ° as shown in fig. 2. Helical motion is 
created to move the fluid inside the channel by the grooves. This 
method provides high efficiency of mixing drug carriers [11]. 
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Fig. 1: Hydroderma flow micromixer for the fabrication of microfluidic drug carriers [12] 
 
 
Fig. 2: Simple microfluidic mixer for the fabrication of microfluidic drug carriers [12] 
 
 
Fig. 3: Staggered herringbone mixer for the fabrication of microfluidic drug carriers [12] 
 
Droplet-based carriers 
It is the most widely used method for the fabrication of carriers with 
high reproduction and homogenous drug-loaded particles. This 
method is also used for the production of microcapsules, 
microbubbles, and microgels [13]. This method produced a particle 
of larger size (microparticles), which are more stable and deliver a 
high amount of drugs for a longer time. T junction, co-flowing, and 
flow-focusing are corner geometries used in the fabrication of drugs 
carriers. T junction two immiscible fluids are mixed by an 
intersection at a point where two channels converge to form a 'T' 
shape. In co-flow, the flow of the fluids is in the same orientation. 
Two microchannels are present, which are immersed in each other. 
The inner channel contains the continuous phase and the outer 
channels have a dispersed phase. Inflow focus both phases are in 
contrast directions and mixed at the intersect present at the end of 
the inner channel as shown in fig. 4 [14].  
Direct delivery of drugs  
Microfluidic devices are also used for the direct delivery of drugs to 
the target tissues. The transdermal delivery is the most important 
method for direct delivery into the skin. The most widely used 
methods for transdermal administration of the drugs are 
hypodermic needles, topical creams, and transdermal patches. The 
skin has a barrier layer stratum corneum layer, which prevents the 
entry of drugs into the body and needles are a very painful mode of 
drug delivery. A new form of a delivery system called the 
microneedles helps to enhance the delivery of the drug by 
penetrating this skin barrier and overcoming the various problems 
associated with the conventional method of delivery. The primary 
principle involves disruption of the skin layer, thus creating micron 
size pathways that lead the drug directly to the epidermis or 
upper dermis region from where the drug can directly go into 
the systemic circulation without facing the barrier. Microneedles 
puncture the skin, excluding the nerve-rich area and get penetrates 
the epidermis of the skin. The drugs transport drugs directly into the 
organs across the skin barriers [15]. Microneedles are sharp and less 
painful, which puncture the skin with a small dimension. After 
puncturing the skin, needles are removed and drugs are inserted 
into the skin in the form of microgels and microlotions. In some 
microneedles, the drugs are coated on the needles and the drugs are 
dissolved into the skin directly. Microneedles are also made up of 
biodegradable material and after the insertion, the microneedles get 
dissolved inside the body, and drugs are released [16]. 
Camptothecin, which is an anticancer drug, has encapsulated with 
polymer polyvinyl alcohol and poly lactic-co-glycolic for better 
delivery in cancer patients. Doxorubicin is another anticancer drug 
that uses microfluidic devices as a carrier for hepatic cancer 
treatment [14]. 
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Fig. 4: Droplets microfluidic platforms (A) T-junction; (B) co-flowing junction and (C) flow-focusing junction [12] 
 
Diagnosis of cancer by microfluidic devices 
Labeled microfluidic devices 
Immunomagnetic affinity-based capture: This method is based on the 
affinity of the target cells. A specific antibody is functionalized to the 
microchannel walls and the microstructure. This method involves two 
strategies positive enrichment in this the sample containing CTCs are 
pumped through the microchannel and the cells with the same affinity 
to the functionalized antibody get captured and the rest of the sample 
move freely through the microchannel. In the negative enrichment, the 
CTCs cells flow freely through the sample and the sample gets 
captured by the functionalized surface [17]. 
A new generation of microfluidic devices are developed by 
combining different methods such as cell immunoaffinity to the 
magnetophoresis in which a force is exerted by a nonuniform 
magnetic field over a superparamagnetic particle. This force helps to 
pull and push the particles according to the magnetic susceptibility 
of particles. If the particle has higher susceptibility than the 
suspending medium, particle is pulled towards the zone of high 
gradient and vice versa [18]. CellSearch device is the only clinically 
approved testing system by FDA for CTCs detection. In this, the 
magnetic field is used to capture CTCs labeled with ferrofluid 
nanoparticles. Then CTCs are stained with pan-cytokeratin C 
biomarker specific for CD45 CTCs. This device is widely used for 
breast, prostate, and colorectal cancer. Isoflux is another device that 
worked on the same technique as above. In this, the sample is 
passed slowly through the device. This method has high sensitivity 
in the detection of CTCs from hepatocellular carcinoma cancer [19, 
20].  
Dielectrophoresis based capture 
In this method, the electrokinetic force is used to capture the CTCs. 
The device has a nonuniform electric field generated by an electrode 
array. This nonuniform electric field induces a polarizing effect on the 
neutral cells. The force exerted is of two types: positive in which the 
particle is attracted to the electric field when the particle is more 
polarized than the medium and negative when the particle is less 
polarized and gets repelled from the electric field [21]. The method 
depends upon the dielectric potential and gradient of the electric field 
square. This method is further categorized into 3 types. eDEP in which 
electrode array is used to generate an electric field square gradient. 
iDEP (Insulator DEP) in which an insulator is added into the (electrode 
DEP) to creates an electric gradient and cDEP (contactless DEP) in 
which liquid electrode is used to generate the electric gradient and 
separated by an insulator from the channel [20]. This method is low 
cost, more specific, and small sample volume. DEP microfluidic devices 
are modified by integrated with the chip to improve the performance 
of the device. The chips are made up of polydimethylsiloxane (PDMS). 
The lap on a chip device is used to detect MCF-7 human breast cancer 
from HCT-116 breast cancer [22]. 
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Labeled free microfluidic devices  
Size based filtration: This method is based on the size of cells and 
filters are used for the separation of cells. CTCs and blood cells are 
separated based on morphology. The sizes of CTCs are in between 
17-55 µm, which is larger than the normal blood cells. VyCap micro 
sieves are an example of a microfluidic device based on the filtration 
system. This device has a silicon nitride membrane with a pore size 
of 5 µm. The sample is passed through the filter and cells get 
separated based on size and morphology [23]. 
Density-based filtration: In this method, separation is done based on 
a density gradient. The sample is centrifuged and blood forms 
different layers: Upper plasma layer, middle buffy coat layer, and at 
bottom RBCs layer based on cell density. The CTCs are identified by 
immune-fluorescence staining [24].  
Chromatography: The sample having the target particle (mobile 
phase) passes through the stationary phase and the particle are 
separated by different speeds. The system of this device is very 
complex. GM-MS has been reported to identify biomarkers of 
various kinds of cancers. HPLC and LC-MS are other useful tools 
reported to detect body fluid and cancer [25]. 
Surface plasmon resonance 
It is an optical bioassay, high sensitivity, and real-time monitoring 
method. It is a label-free method which depends upon the changes in 
the refractive index close to the surface. The method depends upon 
the resonant oscillation of free electrons on the surface of the metal 
which presents near a dielectric medium. When a molecule binds to 
the metal surface the dielectric properties of the interface change 
and detected by the photodetector [18]. Various studies have shown 
the detection of cancer cells by this system such as VEGF breast 
cancer (100 pg/ml), AFP liver cancer (500 pg/ml), f-PSA prostate 
cancer (100 fg/ml) [26, 27, 28]. This method is improved by 
installing a CCD camera for image capturing [29]. Also, the system is 
combined with the classical sandwich enzyme assay. In this, the 
system antigen is a sandwich between a primary antibody and a 
labeled antibody [30]. This is system is also coated with 
nanoparticles (Au and silver) which amplify the signal and are 
rapidly detected by the detector [31]. 
Other microfluidic systems  
A system was prepared for the detection of A549 cancer cells by 
integrating the surface of a microfluidic device with a piezoelectric 
sensor. The system works by suspending superparamagnetic 
microbeads into a nickel pillar array and the detection was done by 
the analyses of the accumulated mass of cells resonant character at the 
piezoelectric sensor. This is a low cost and high efficient system [32]. 
A biomicrofluidic device was designed to detect a breast cancer cell 
line (MCF-7). The system is fabricated by lithography based 
microfabrication technique. In this device, a weir-type filter is 
present which capture the fluorescent-labeled cells. The detection is 
seven times stronger than the conventional glass slide method [33]. 
GILUPI cell collector is an antibody-coated device, which captures 
the target cells in vivo. The device is inserted through a standard 
venous cannula into the cancer patient's vein. The blood is volume-
limited in the traditional immunoaffinity devices overpower as it can 
detect rare CTCs in 1.5-3 liters of blood in 30 min. This device 
consists of stainless steel wire (16 mm) with a rounded tip (2 mm). 
The tip has a 3D antEpCAM antibody functioned layer which 
captures the rare CTCs flowing in the blood of cancer patients [34]. 
A label-free novel microfluidic device was designed for the 
improvement of the diagnostic technique. In this, the cell size and 
deformability are used as a biomarker for diagnosis. A high 
throughput optical detection system was integrated with the lateral 
equilibrium position of cell deformability [35]. Exosomes and ctDNA 
are also used as a biomarker in cancer detection. CTCs are very rare 
in the early stage of cancer so very difficult to detect. Exosomes have 
reported for ready detection of the early stage of pancreatic, 
melanoma, and glioblastoma cancer. ctDNA is the fragments of DNA 
circulating the blood system by dying cancer cells. The ctDNA can be 
detected by using a technique like PCR, RT-PCR, and next-generation 
sequencing [36]. Recently new microfluidic devices have developed 
for the better detection of rare CTCs as shown in table 1. 
  
Table 1: Microfluidic devices for the detection of rare circulating tumor cells 
S. No. Microfluidic devices Material  Detection References 
1 Chitosan microcarriers PDMS Breast cancer cells  [37] 
2 Rapa delivery PDMS RAPA drug delivery  [38] 
3 Labyrinth microfluidic devices PDMS channel bonded to glass slides  Hepatocellular carcinoma  [39] 
4 A novel integrated microfluidic device PDMS Colorectal cancer  [40] 
5 optically-induced-dielectrophoresis (ODEP)-based 
microfluidic system  
- Leukocytes  [41] 
6 3D scaffold gelatin-microchip PDMS scaffold skeleton MCF-7 cells  [42] 
7 Hyaluronic acid-functionalized electrospun PLGA 
nanofibers embedded in a microfluidic chip 
PLGA  CD44+carcinoma  [43] 
8 DNA-templated magnetic nanoparticle-quantum dot 
(QD)-aptamer copolymers (MQAPs)  
PDMS Rare CTCs  [44] 
 
Drug toxicity 
Microfluidic devices are used to create a well-controlled 
microenvironment. This microenvironment provides more 
advantages than conventional methods to check drug toxicity. The 
advantages of the microfluidic system over other methods are more 
optimum conditions as in vivo system. The current drug methods are 
in vitro tests in labs and animal models to check the activity and 
toxicity screening of drugs [45]. The screening of drug toxicity is a 
key feature in the development of the new drug. The preclinical 
trials using animal models are very expensive and low accuracy than 
the actual in vivo activity of drugs. Only 10 % of drugs get to pass 
through the Phase I clinical trials and approved for marketing [46]. 
Microfluidic devices are emerging as an in vitro system for the 
screening of drug toxicity prediction in the in vivo environment. The 
various microfluidic devices are developed which mimic the 
microenvironment of the target organs and check the drug toxicity 
in organ-level conditions [47]. 
Liver-on-chip 
The liver is an important organ for the screening of drug toxicity. All 
the metabolism of compounds occurs in the liver and the toxicity 
analysis in microfluidic devices having the same effect as in vivo liver 
system provides the actual activity of that drug. The metabolism can 
also impact the drugs and the drug carrier's liver on-chip is an 
important tool for drug toxicity [48]. The 3D microfluidic devices 
resemble more closely the in vivo situation inside the organ system. 
The controlled flow of fluids can be blood flow. In vitro testing using 
3D models of microfluidic have hepatocytes cells and with metabolic 
enzymes and hepatic transporters [49].  
The pH, composition of media, and oxygen requirement can be easily 
controlled by the fluid flow into the microfluidic devices. The devices 
also reproduce the metabolic process equal to the in vivo conditions. 
The system also generates concentration gradients, pumps, valves, and 
other organs [50]. The microdevices are made up of plastic, glass, 
Tripathi et al. 
Int J App Pharm, Vol 13, Issue 1, 2021, 95-102 
99 
elastomers materials and are easily detectable. In liver-based 
microfluidic devices various in vitro models are used such as cell-free, 
subcellular fractions cell lines, primary hepatocytes cells, and tissues. 
The uses of different cell lines are used in the study to analyze the 
molecular mechanisms of drug toxicity. The drug toxicity screening 
can be more accurately predicted by the use of different cell lines in 
one microfluidic device. Most of the drugs are metabolized in the liver 
cells and after that, it can produce toxic metabolites having an impact 
on other organs [51]. In 2004 Shular and coworker designed a 
microfluidic system for the screening of drug toxicity on multiple 
organs. In this microsystem made up of silicon and have three 
different cell lines (lung, adipocytes, and liver cell). Naphthalene can 
be analyzed by using this microfluidic system as this drug can cause 
drug toxicity on the lung cells. 3D-μFCCS is another 3D microfluidic 
device using kidney, adipocyte, and liver cells separately integrated 
into PDMS material [52]. Lung on-chip is a similar organ on a chip 
microfluidic devices are used to check the toxicity of drugs on the lung 
epithelium cells [53]. The kidney on-chip system had designed to 
study drug toxicity on the renal cells. In this system, renal and nephron 
cells are integrated into a PDMS chip with a continuous flow of inner 
tubular fluid [54]. Heart on-chip system analyses the cardiac tissue 
contraction under the exposure of different chemical or drugs [55]. 
Brain on-chip is used to detect the effect of drugs on endothelial cells 
and brain interactions. Human-on-chip is used to screening the 
toxicity and metabolism of drugs at an organism level. In this system 
interconnected chambers having different organ cells are connected 
with a microfluidic circulatory system [56].  
 
 
Fig. 5: bioMEMS microfluidic device actuated with ‘microteeth’ [57] 
 
BioMEMS is such devices developed by Sandia National laboratories, 
USA for the safe delivery of proteins or pharmaceuticals product to 
specific target cells. This device contains silicon microteeth that trap 
single red blood cell and pump it through 20 µm channel as shown in 
fig. 5 [58].  
Advantages and drawback of microfluidic devices 
The microfluidic devices are based on the highly targeted delivery of 
specific drugs at a specific time. There is no sufficient toxicological 
data for the newly synthesized drugs like HIV and anticancer 
cytotoxic drugs doxorubicin, rubitecan, gemcitabine, and 
daunerubicin. These drugs were also observed to have an apoptosis 
effect on the adjacent normal cells. The concentrations of drugs are 
also a very critical point in drug delivery. The drugs have a minimum 
threshold functional concentration and the slight amount above 
threshold concentration could cause irreversible damage to 
functional organs [59]. Novel drug delivery systems are used to 
control the release of drugs to a specific site and also target to 
disease site [60].  
The resemblance between the active sites of drug receptors and 
other proteins can also cause various side effects. The microfluidic 
devices can deliver the drugs to specific target sites in a minimum 
functional concentration rather than the traditional nonspecific 
drug delivery systems. The nonlinear drug delivery is also 
problems in the case of growth hormones delivery to the specific 
target tissue as it should be very precise for the proliferation of 
the tissue and the linear delivery could be achieved by the 
microfluidic devices so that no damage to the acute organs. The 
microfluidic drug delivery system ensures the bioavailability of 
drugs at specific target receptors with the desired dose of release 
[61]. Laminar flow is characteristic feature of microfluidic system 
and it depends upon Reynolds number (Re). Re is a dimensionless 
number represent the viscous flow of fluids. At low Re the fluid 
moves smoothly and shows a laminar flow. At high Re the mixing 
is not linear but shows turbulent flow as shown in fig. 6. In micro-
scale system laminar flow is observed and in macro-scale 
turbulent flow is dominant [62]. 
The roughness of the surface is a very important parameter in the 
micro-scale systems as the surface area to volume ratio increases so 
the flow of fluid depends upon the surface phenomenon. Roughness 
affects fluid flow and creates a pressure drop. To overcome this 
problem nano finished microchannel with elevated temperature and 
less drops in the pressure are used [64]. The friction factor is 
another parameter that has been observed over a small range of 
relative roughness under low Re. In the blood flow through the 
microchannels, surface roughness has an impact on the blood 
viscosity and blood flow [65]. 
  
 
Fig. 6: Laminar and turbulent flow in microfluidic system [63] 
 
The chemical reaction between the liquid and material is a major 
problem. This causes fouling in which the sample and reagents get 
stick to the surface of the microchannel device. The fouling in the 
channel can cause clogging and encrustment of the system [66]. To 
avoid the fouling cleaning process should be done. For example in 
blood flow there are some macromolecules like NaCl which can bind 
to the surface or the uncharged proteins upon unfolding can become 
charged and can react with the materials; the fouling can also affect 
the pressure as the clog of molecule creates hindrance in the fluid 
flow and also the molecule which gets clogged will be missing from 
the samples and it could cause inaccuracy in the results [67]. 
The fouling can cause more problems in the diagnosis with time as 
more samples will be passed from the microchannel. To overcome 
the problem of fouling in glass-based microchannel coating with 
bovine serum albumin can be done but this solution has many 
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drawbacks as the small molecules can be lost due to adsorption to 
the coated surface [68]. Self-assembled monolayer coating and 
PDMS materials have been used to overcome this problem. But these 
materials are also not the 100% solution to the fouling of surface 
and any kind of research is going on to solve this problem [69]. In 
small scales, the regulation of capillary forces is very difficult and it 
affects the flow rate of the liquid in a microchannel. For the 
regulation of capillary flow valves, electrochemical and static forces 
are employed in microchannel devices. In glass-based microfluidic 
devices, the weak capillary force is observed so the fluid moves very 
slowly from the glass microchannels. Nanorods are employed to 
improve the capillary force [70]. Different materials like glass, 
silicon and polymer are used for fabrication of microfluidic devices 
as described in table 2. 
  
Table 2: Different materials for the fabrication of microfluidic devices 
S. No. Microfluidic chip 
material 
Application Disadvantages References 
1 Silicon High resistance towards organic solvents, highly stable, 
internees, high resistance for oxidation  
High cost, not easy to handle, less 
flexible, opaque in color  
[71] 
2 Glass Transparent, high thermal conductivity High cost, hardness  [72] 
3 PDMS Easy to fabricate, stretchable, Transparent, Suitable for valve 
and pumps fabrication, inertness, less cost of fabrication  
Absorption of hydrophobic 
molecules  
[73] 
4 Thermostat polyester Insoluble, inexpensive, don’t absorb biomolecules Stiff, high cost  [74] 
5 Thermoplastics  Highly crosslinked polymer, high production at low cost Rigidity  [75] 
6 Paper microfluidic Flexible, cheap, easy degradation  Complex fabrication  [76] 
7 Hydrogels Highly porous, suitable for cellular biology studies, 
Biodegradable, low toxicity 
Limited hydrophobic drug 




Microfluidic technologies are an important role in the field of a 
cancer diagnosis as well as the progress of medicine. Microfluidic 
systems have emerged as a tool for direct and localized drug 
delivery to target sites. The advantage of these systems is the 
delivery of an exact and small quantity of drug doses, reducing the 
need for using high concentrations of drugs with significant side 
effects. The diagnosis of CTCs is a better alternative to the 
conventional biopsy for cancer detection. Microfluidic devices are a 
potential tool that enables earlier cancer molecular diagnosis. This 
method is for better-targeted cancer therapy and improved follow-
up care. Novel microfluidic devices with improved design should be 
employed for more precise drug delivery and diagnosis. 
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